Study of Profound's prostate cancer device gets green light

09/19/2013 | MassDevice.com (Boston)

The FDA has granted Profound Medical investigational device exemption approval to conduct a clinical study of its device that uses real-time MRI guidance and thermal ultrasound to treat patients with localized prostate cancer. The Canadian company plans to start patient enrollment in the trial in late 2013.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA